Exudative Age-related Macular Degeneration Clinical Trial
Official title:
FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration
The purpose of this study is to investigate the safety and efficacy of a combined fixed-interval and a pro re nata (PRN) regimens of ranibizumab (FUSION regimen) for the treatment of exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA) at baseline. To establish whether similar efficacy to monthly regimens can be achieved with fewer injections, even in patients with good VA.
This is a prospective, open-label, consecutive interventional case series in treatment-naïve patients with exudative AMD. A loading phase of 2-3 injections is followed by a fixed-interval regimen of injections combined with a pro re nata regimen for 12 months. Endpoints include VA, presence of fluid at spectral domain optical coherent tomography (SD-OCT), adverse events and number of injections administered. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01950741 -
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
| Recruiting |
NCT01608113 -
Long-term Follow-up of Subfoveal Neovascular AMD
|
N/A | |
| Completed |
NCT01404845 -
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
|
N/A | |
| Completed |
NCT01213082 -
ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01961414 -
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
|
Phase 4 | |
| Completed |
NCT01810042 -
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
|
Phase 4 | |
| Completed |
NCT01304693 -
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04640272 -
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
|
Phase 2 | |
| Active, not recruiting |
NCT02976194 -
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
| Enrolling by invitation |
NCT05539235 -
Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
|
Phase 2/Phase 3 | |
| Completed |
NCT02355028 -
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
|
Phase 2 | |
| Unknown status |
NCT02089503 -
Monocentric Retrospective Observational Study on Patients With Macular Degeneration
|
N/A | |
| Completed |
NCT01796964 -
Efficacy and Safety Study of ESBA1008 Versus EYLEA®
|
Phase 2 | |
| Completed |
NCT01127360 -
LUCAS (Lucentis Compared to Avastin Study)
|
Phase 4 | |
| Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
| Recruiting |
NCT02328209 -
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
|
N/A | |
| Completed |
NCT01849692 -
ESBA1008 Microvolume Study
|
Phase 2 | |
| Completed |
NCT01157065 -
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT04138420 -
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
|
||
| Completed |
NCT03744806 -
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
|